α1-Acid Glycoprotein Has the Potential to Serve as a Biomimetic Drug Delivery Carrier for Anticancer Agents

Kotaro Matsusaka, Yu Ishima, Hitoshi Maeda, Ryo Kinoshita, S. Ichimizu, Kazuaki Taguchi, Victor Tuan Giam Chuang, Koji Nishi, Keishi Yamasaki, Masaki Otagiri, Hiroshi Watanabe, Toru Maruyama

Research output: Contribution to journalArticle

Abstract

Nanosize plasma proteins could be used as a biomimetic drug delivery system (DDS) for cancer treatment when loaded with anticancer drugs based on the fact that plasma proteins can serve as a source of nutrients for cancer cells. This prompted us to investigate the potential of α1-acid glycoprotein (AGP) for this role because it is a nanosize plasma protein and binds a variety of anticancer agents. Pharmacokinetic analyses indicated that AGP is distributed more extensively in tumor tissue than human serum albumin, which was already established as a cancer DDS carrier. AGP is possibly being incorporated into tumor cells via endocytosis pathways. Moreover, a synthetic AGP-derived peptide which possesses a high ability to form an α-helix, as deduced from the primary structure of AGP, was also taken up by the tumor cells. AGP loaded with anticancer agents, such as paclitaxel or nitric oxide, efficiently induced tumor cell death. These results suggest that AGP has the potential to be a novel DDS carrier for anticancer agents.

Original languageEnglish
JournalJournal of Pharmaceutical Sciences
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Biomimetics
Drug Carriers
Antineoplastic Agents
Glycoproteins
Acids
Drug Delivery Systems
Neoplasms
Blood Proteins
Endocytosis
Paclitaxel
Serum Albumin
Nitric Oxide
Cell Death
Pharmacokinetics
Food
Peptides
Pharmaceutical Preparations

Keywords

  • anticancer agents
  • cancer
  • DDS carrier
  • orosomucoid
  • α-acid glycoprotein

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

α1-Acid Glycoprotein Has the Potential to Serve as a Biomimetic Drug Delivery Carrier for Anticancer Agents. / Matsusaka, Kotaro; Ishima, Yu; Maeda, Hitoshi; Kinoshita, Ryo; Ichimizu, S.; Taguchi, Kazuaki; Giam Chuang, Victor Tuan; Nishi, Koji; Yamasaki, Keishi; Otagiri, Masaki; Watanabe, Hiroshi; Maruyama, Toru.

In: Journal of Pharmaceutical Sciences, 01.01.2019.

Research output: Contribution to journalArticle

Matsusaka, K, Ishima, Y, Maeda, H, Kinoshita, R, Ichimizu, S, Taguchi, K, Giam Chuang, VT, Nishi, K, Yamasaki, K, Otagiri, M, Watanabe, H & Maruyama, T 2019, 'α1-Acid Glycoprotein Has the Potential to Serve as a Biomimetic Drug Delivery Carrier for Anticancer Agents', Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.xphs.2019.07.002
Matsusaka, Kotaro ; Ishima, Yu ; Maeda, Hitoshi ; Kinoshita, Ryo ; Ichimizu, S. ; Taguchi, Kazuaki ; Giam Chuang, Victor Tuan ; Nishi, Koji ; Yamasaki, Keishi ; Otagiri, Masaki ; Watanabe, Hiroshi ; Maruyama, Toru. / α1-Acid Glycoprotein Has the Potential to Serve as a Biomimetic Drug Delivery Carrier for Anticancer Agents. In: Journal of Pharmaceutical Sciences. 2019.
@article{33597c9542a84692a5abd11c813f76bc,
title = "α1-Acid Glycoprotein Has the Potential to Serve as a Biomimetic Drug Delivery Carrier for Anticancer Agents",
abstract = "Nanosize plasma proteins could be used as a biomimetic drug delivery system (DDS) for cancer treatment when loaded with anticancer drugs based on the fact that plasma proteins can serve as a source of nutrients for cancer cells. This prompted us to investigate the potential of α1-acid glycoprotein (AGP) for this role because it is a nanosize plasma protein and binds a variety of anticancer agents. Pharmacokinetic analyses indicated that AGP is distributed more extensively in tumor tissue than human serum albumin, which was already established as a cancer DDS carrier. AGP is possibly being incorporated into tumor cells via endocytosis pathways. Moreover, a synthetic AGP-derived peptide which possesses a high ability to form an α-helix, as deduced from the primary structure of AGP, was also taken up by the tumor cells. AGP loaded with anticancer agents, such as paclitaxel or nitric oxide, efficiently induced tumor cell death. These results suggest that AGP has the potential to be a novel DDS carrier for anticancer agents.",
keywords = "anticancer agents, cancer, DDS carrier, orosomucoid, α-acid glycoprotein",
author = "Kotaro Matsusaka and Yu Ishima and Hitoshi Maeda and Ryo Kinoshita and S. Ichimizu and Kazuaki Taguchi and {Giam Chuang}, {Victor Tuan} and Koji Nishi and Keishi Yamasaki and Masaki Otagiri and Hiroshi Watanabe and Toru Maruyama",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.xphs.2019.07.002",
language = "English",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - α1-Acid Glycoprotein Has the Potential to Serve as a Biomimetic Drug Delivery Carrier for Anticancer Agents

AU - Matsusaka, Kotaro

AU - Ishima, Yu

AU - Maeda, Hitoshi

AU - Kinoshita, Ryo

AU - Ichimizu, S.

AU - Taguchi, Kazuaki

AU - Giam Chuang, Victor Tuan

AU - Nishi, Koji

AU - Yamasaki, Keishi

AU - Otagiri, Masaki

AU - Watanabe, Hiroshi

AU - Maruyama, Toru

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Nanosize plasma proteins could be used as a biomimetic drug delivery system (DDS) for cancer treatment when loaded with anticancer drugs based on the fact that plasma proteins can serve as a source of nutrients for cancer cells. This prompted us to investigate the potential of α1-acid glycoprotein (AGP) for this role because it is a nanosize plasma protein and binds a variety of anticancer agents. Pharmacokinetic analyses indicated that AGP is distributed more extensively in tumor tissue than human serum albumin, which was already established as a cancer DDS carrier. AGP is possibly being incorporated into tumor cells via endocytosis pathways. Moreover, a synthetic AGP-derived peptide which possesses a high ability to form an α-helix, as deduced from the primary structure of AGP, was also taken up by the tumor cells. AGP loaded with anticancer agents, such as paclitaxel or nitric oxide, efficiently induced tumor cell death. These results suggest that AGP has the potential to be a novel DDS carrier for anticancer agents.

AB - Nanosize plasma proteins could be used as a biomimetic drug delivery system (DDS) for cancer treatment when loaded with anticancer drugs based on the fact that plasma proteins can serve as a source of nutrients for cancer cells. This prompted us to investigate the potential of α1-acid glycoprotein (AGP) for this role because it is a nanosize plasma protein and binds a variety of anticancer agents. Pharmacokinetic analyses indicated that AGP is distributed more extensively in tumor tissue than human serum albumin, which was already established as a cancer DDS carrier. AGP is possibly being incorporated into tumor cells via endocytosis pathways. Moreover, a synthetic AGP-derived peptide which possesses a high ability to form an α-helix, as deduced from the primary structure of AGP, was also taken up by the tumor cells. AGP loaded with anticancer agents, such as paclitaxel or nitric oxide, efficiently induced tumor cell death. These results suggest that AGP has the potential to be a novel DDS carrier for anticancer agents.

KW - anticancer agents

KW - cancer

KW - DDS carrier

KW - orosomucoid

KW - α-acid glycoprotein

UR - http://www.scopus.com/inward/record.url?scp=85070505990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070505990&partnerID=8YFLogxK

U2 - 10.1016/j.xphs.2019.07.002

DO - 10.1016/j.xphs.2019.07.002

M3 - Article

C2 - 31288036

AN - SCOPUS:85070505990

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

ER -